Pfizer has completed its acquisition of Therachon Holding AG, a privately held clinical-stage biotechnology company, in a deal worth up to $810 million.

Under the agreement, Pfizer acquired Therachon for $340 million with an additional $470 million in milestone payments conditioned on the development and commercialization of TA-46, an investigational medicine for treating achondroplasia, a genetic condition and the most common form of short-limb dwarfism.

Source: Pfizer